Advances in Brain Health: Blood Biomarkers (BBMs) in Alzheimer’s Dementia (AD)
Free On Demand CME
You will be able to access pertinent content after the activity concludes. Continued access to the included visual aids will help you familiarize yourself with images of various conditions.
Alzheimer’s Dementia (AD) remains a challenging clinical diagnosis, particularly in the early stages of cognitive decline. With a shortage of dementia care specialists and direct care workers, family physicians play a critical role in bridging the care gap.
This enduring self-study activity is designed to enhance your knowledge and clinical competence in caring for patients with cognitive decline and Alzheimer’s disease specifically.
The approximately 4-hour CME course will address key educational gaps identified through research and the AAFP’s 2024 Voices of Alzheimer’s survey.
- Addressing barriers to implementing annual cognitive screening
- BBM test selection criteria and test characteristics
- Diagnosis and care pathways, including next steps following a positive cognitive impairment result
- Basic science and technology behind BBMs
Alzheimer’s Dementia (AD) remains a challenging clinical diagnosis, particularly in the early stages of cognitive decline. With a shortage of dementia care specialists and direct care workers, family physicians play a critical role in bridging the care gap.
This enduring self-study activity is designed to enhance your knowledge and clinical competence in caring for patients with cognitive decline and Alzheimer’s disease specifically.
The approximately 4-hour CME course will address key educational gaps identified through research and the AAFP’s 2024 Voices of Alzheimer’s survey.
- Addressing barriers to implementing annual cognitive screening
- BBM test selection criteria and test characteristics
- Diagnosis and care pathways, including next steps following a positive cognitive impairment result
- Basic science and technology behind BBMs
Learning Objectives
Recognize the role of family physicians in the early detection and treatment of Alzheimer’s Disease (AD).
Discuss the science behind blood biomarkers (BBMs) and their importance in diagnosing AD.
Identify and evaluate different types of BBMs for AD, including their key characteristics and selection criteria.
Develop effective diagnosis and care pathways for patients with positive cognitive impairment results.
Enhance communication strategies to educate patients about cognitive health and promote best practices for preventing cognitive decline.
Translate knowledge of BBMs to improve patient outcomes through practical applications and consideration of their use in clinical practice.
Additional Details
The Role of Family Physicians in Early Detection of Alzheimer’s Disease
Ariel Cole, MD, FAAFP
The Science Behind Blood Biomarkers (BBMs) for Alzheimer Disease: What Family Physicians Need to Know
Diana P. Summanwar, MD; Deanna R. Willis, MD, FAAFP
Next Steps After a Positive Cognitive Impairment Screening: Diagnosis and Care Pathways
Diana P. Summanwar, MD; Deanna R. Willis, MD, FAAFP
Educating Patients and Care Partners on Cognitive Health: Strategies and Best Practices
Ecler Jaqua, MD, MBA, FAAFP, AGSF, FACLM
From Theory to Practice: Applying Blood Biomarkers to Improve Patient Outcomes
Ariel Cole, MD, FAAFP; Ecler Jaqua, MD, MBA, FAAFP, AGSF, FACLM; Diana P. Summanwar, MD; Deanna R. Willis, MD, FAAFP
This CME activity is supported by an educational grant to the AAFP from USAgainstAlzheimer's.